Ilana Meyer is a member of Foley & Lardner’s Health Care Practice Group. She began at Foley as a summer associate. While in law school, she worked as a Judicial Intern for Senior Judge Paul L. Friedman of the United States District Court for the District of Columbia. Most recently, Ilana interned in the Office of General Counsel for the Dana-Farber Cancer Institute working on regulatory and policy issues. She also has experience within a multidisciplinary team, performing complex clinical ethics consultations.
演讲和出版物
- Co-author, “Massachusetts: New Year, New Law — Governor Signs “An Act enhancing the market review process” (House Bill No. 5159),” Health Care Law Today (January 14, 2025)
- Co-author, “Massachusetts Health Care Act Dies at the End of Legislative Session But Previews Sweeping Changes for the Health Care Industry,” Health Care Law Today (August 5, 2024)
- Co-author, “Clinical Trials: FDA Issues Finalized Charging Guidance for Investigational Drug Use,” Health Care Law Today (March 13, 2024)
富理达律师为美国卫生法协会的《代表医生手册》撰稿
Foley & Lardner LLP 律师 Jana Kolarik、Claire Marblestone、Illana Meyer、Sheridan Organ 和 Kate Pamperin 为美国卫生法协会 (AHLA) 的《代表医生手册》第五版撰稿。
马萨诸塞州:新年新法——州长签署《加强市场审查程序法案》(众议院第5159号法案)
2025年1月8日,州长莫拉·希利签署了第5159号众议院法案《加强市场审查程序法案》,使其正式成为法律。
Massachusetts Health Care Act Dies at the End of Legislative Session But Previews Sweeping Changes for the Health Care Industry
The Massachusetts legislative session officially closed on August 1, 2024 after an unusual half day extension.
雪佛龙原则的终结对联邦医疗保健计划意味着什么?
2024 年 6 月 28 日,在备受关注的洛珀-布莱特企业诉雷蒙多案中,最高法院驳回了雪佛龙尊重原则。
Clinical Trials: FDA Issues Finalized Charging Guidance for Investigational Drug Use
In February 2024, the U.S. Food and Drug Administration published its finalized guidance concerning its investigational drug charging regulations.